Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 5/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.48 |
| ▸ | RELA | Q04206 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15620334 | 0.91 | NFKB1 (0.48) | NFKB1NFKB2RELACYP3A4MEN1 | |
| SCHEMBL14523859 | 0.75 | PTPN1 (0.47) | NFKB1NFKB2RELACYP3A4MEN1 | |
| SCHEMBL25200700 | 0.72 | PTPN1 (0.60) | NFKB1NFKB2RELACYP3A4MEN1 | |
| SCHEMBL30384556 | 0.72 | PTPN1 (0.60) | NFKB1NFKB2RELACYP3A4MEN1 | |
| SCHEMBL4977891 | 0.72 | OSBP (0.43) | NFKB1NFKB2RELACYP3A4MEN1 | |
| SCHEMBL4977898 | 0.72 | OSBP (0.43) | NFKB1NFKB2RELACYP3A4MEN1 | |
| SCHEMBL12599532 | 0.71 | NFKB1 (0.50) | NFKB1NFKB2RELACYP3A4MEN1 | |
| SCHEMBL25301405 | 0.71 | NFKB1 (0.50) | NFKB1NFKB2RELACYP3A4MAPT | |
| SCHEMBL5519370 | 0.71 | PTPN1 (0.51) | NFKB1NFKB2RELACYP3A4MEN1 | |
| SCHEMBL4982221 | 0.71 | PTPN1 (0.51) | NFKB1NFKB2RELACYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345597-A2 | PKC DELTA INHIBITORS FOR USE AS THERAPEUTICS | Faller & Williams Technology, LLC (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-2897610-B1 | PKC DELTA INHIBITORS FOR USE AS THERAPEUTICS | FALLER & WILLIAMS TECH LLC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9844534-B2 | PKC delta inhibitors for use as therapeutics | FALLER & WILLIAMS TECHNOLOGY, LLC (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170252322-A1 | PKC Delta Inhibitors for use as Therapeutics | FALLER & WILLIAMS TECHNOLOGY, LLC (US) | 2017-09-07 | — | — | US | disclosed |
| US-9572793-B2 | PKC delta inhibitors for use as therapeutics | FALLER & WILLIAMS TECHNOLOGY, LLC (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160250183-A1 | PKC Delta Inhibitors for use as Therapeutics | FALLER & WILLIAMS TECHNOLOGY, LLC | 2016-09-01 | — | — | US | disclosed |
| US-9364460-B2 | PKC delta inhibitors for use as therapeutics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-14 | — | — | US | disclosed |
| US-20150283114-A1 | PKC Delta Inhibitors for use as Therapeutics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-08 | — | — | US | disclosed |
| EP-2897610-A2 | PKC DELTA INHIBITORS FOR USE AS THERAPEUTICS | Faller, Douglas V. (US) | 2015-07-29 | — | — | EP | disclosed |
| WO-2014047328-A2 | PKC DELTA INHIBITORS FOR USE AS THERAPEUTICS | FALLER DOUGLAS V (US) | 2014-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170252322-A1 | PKC Delta Inhibitors for use as Therapeutics | PRKCH, PRKCD, PRKCI | NFKB1 1903/4885NFKB2 2112/4885RELA 3082/4885 |
| US-20160250183-A1 | PKC Delta Inhibitors for use as Therapeutics | PRKCH, PRKCD, PRKCI | NFKB1 1903/4885NFKB2 2112/4885RELA 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.